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Background: Some children with autism spectrum disorders (ASD) are characterized by fluctuating behavioral
symptoms following immune insults, persistent gastrointestinal (GI) symptoms, and a lack of response to the
first-line intervention measures. These children have been categorized as the ASD-inflammatory subtype (ASD-IS)
for this study. We reported a high prevalence of non-IgE mediated food allergy (NFA) in young ASD children before,
but not all ASD/NFA children reveal such clinical features of ASD-IS. This study addressed whether behavioral
changes of ASD-IS are associated with innate immune abnormalities manifested in isolated peripheral blood (PB)
monocytes (Mo), major innate immune cells in the PB.
Methods: This study includes three groups of ASD subjects (ASD-IS subjects (N = 24), ASD controls with a history
of NFA (ASD/NFA (N = 20), and ASD/non-NFA controls (N = 20)) and three groups of non-ASD controls (non-ASD/NFA
subjects (N = 16), those diagnosed with pediatric acute onset-neuropsychiatric syndrome (PANS, N = 18), and normal
controls without NFA or PANS (N = 16)). Functions of purified PB Mo were assessed by measuring the production of
inflammatory and counter-regulatory cytokines with or without stimuli of innate immunity (lipopolysaccharide (LPS),
zymosan, CL097, and candida heat extracts as a source of β-lactam). In ASD-IS and PANS subjects, these assays were
done in the state of behavioral exacerbation (‘flare’) and in the stable (‘non-flare’) condition. ASD-IS children in the ‘flare’
state revealed worsening irritability, lethargy and hyperactivity.
Results: ‘Flare’ ASD-IS PB Mo produced higher amounts of inflammatory cytokines (IL-1β and IL-6) without stimuli than
‘non-flare’ ASD-IS cells. With zymosan, ‘flare’ ASD-IS cells produced more IL-1β than most control cells,
despite spontaneous production of large amounts of IL-1ß. Moreover, ‘flare’ ASD-IS Mo produced less IL-10, a
counterregulatory cytokine, in response to stimuli than ‘non-flare’ cells or other control cells. These changes were
not observed in PANS cells.
Conclusions: We observed an imbalance in the production of inflammatory (IL-1ß and IL-6) and counterregulatory
(IL-10) cytokines by ‘flare’ ASD-IS monocytes, which may indicate an association between intrinsic abnormalities of
PB Mo and changes in behavioral symptoms in the ASD-IS subjects.
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ASD are a behaviorally defined syndrome that consists
of a heterogeneous group of neurodevelopmental disor-
ders [1]. Various gene mutations or microdeletion syn-
dromes are known to cause ASD behavioral symptoms;
however, single gene mutations are likely to account for
only a small fraction of ASD cases [2]. In the majority of
ASD subjects, no causative gene mutations have been
identified. In these cases, it is more likely that complex
interactions among multiple genetic and environmental
factors contribute to the onset and progress of ASD, as
seen in other polygenic diseases.
Currently, first-line treatment measures for ASD are
behavioral and pharmacological interventions. Unfortu-
nately, favorable responses to these measures are not
universally achieved; some ASD patients respond well to
these measures, while others do not. This is partly attrib-
uted to both the heterogeneity of the ASD population [1]
and a high frequency of comorbid medical conditions that
may affect behavioral symptoms through pain and discom-
fort [3]. At this time, there are no objective biomarkers for
identifying the children who will not be responsive to the
first-line therapeutic measures.
Although there are alternative treatments, including
those proposed by practitioners of complementary and
alternative medicines (CAM) [4,5], these are not univer-
sally effective either, and research has not shown which
are beneficial to what types (subgroups) of ASD subjects.
There is also a lack of both reliable objective biomarkers
and understanding of the mechanisms of actions [6].
Parents of ASD children may turn to such CAM treat-
ments, hoping for the best. There is an urgent need for
identifying objective biomarkers that may guide optimal
effective measures for ASD children who fail to respond
to the first-line intervention measures.
However, the etiology of poor responses is also multifac-
torial, and it is extremely difficult to identify biomarkers
by focusing on ‘poor responders’ to conventional first line
treatments. Previous genetic workups indicate that muta-
tional analysis may not be practical for segregating ASD
subjects who have an apparent involvement of multiple
genes [1]. Instead, it may be more feasible to focus on
ASD children who are not only poor responders but also
have objective clinical and laboratory characteristics that
are distinguishable from other ASD subjects. The ASD-IS
children described in our previous studies, as detailed in
the next paragraph, may be ideal for such a purpose
In our pediatric allergy/immunology (AI) clinic, we
have evaluated a substantial number of ASD children
for possible food allergy (FA) and underlying immune
condition. Evaluations of these ASD children led us to
recognize that some of them manifest clinical features
indicating immunodysregulation and/or chronic inflam-
mation. Namely, these children exhibit chronic and/orrecurrent sino-pulmonary infection; adverse reactions
to multiple medications; persistent GI symptoms with
high frequency of NFA; and prolonged courses of illness.
Moreover, these children do not respond well to pharma-
cological and behavioral intervention measures per paren-
tal report [7,8]. In this study, we categorized such ASD
subjects as ASD-IS. Further studies of these children,
using peripheral blood mononuclear cells (PBMCs), re-
vealed abnormalities of innate immune responses that
were distinguishable from both ASD and normal controls
[9]. Changes in transcriptional profiles of isolated PB Mo,
which did not overlap with those found in either the ASD
and normal controls, were also found [9]. Based on these
findings, we hypothesized that ASD-IS children have dis-
tinguishable innate immune abnormalities, which can be
associated with behavioral changes following immune in-
sults, typically microbial infection.
It should also be noted that our previous results revealed
discrepancies between transcriptional profiles of PB Mo
and protein levels of cytokine produced by PBMCs, a mix-
ture of lymphocytes, PB Mo, and other lineage cells. Des-
pite the upregulation of mRNA of various cytokines by PB
Mo, the production of such cytokines by PBMCs was
lower in ASD-IS subjects; stimulants used were targeted
to PB Mo [9]. This could be associated with the influence
of cells other than PB Mo, such as regulatory T cells (Treg
cells) or suppressive (tolerizing) dendritic cells (DCs) con-
tained in PBMCs. Alternatively, post-transcriptional regu-
lation in PB Mo, such as those exerted by microRNA
(miRNA) [10,11], may also affect the protein levels of cy-
tokines depending on the stage of PB Mo activation. We
hypothesized that if intrinsic post-translational regulation
has a role in the discrepancy between protein and mRNA
expression of cytokines, isolated PB Mo may reveal dis-
tinct patterns of cytokine production depending on the
activated state of PB Mo. That is, post-transcriptional
regulation exerted by miRNA and other factors are ex-
pected to change rapidly depending on the activated stage
of PB Mo [10]. It should also be noted that such changes
of post-transcriptional regulation may affect the neuroim-
mune network [12]. Interestingly, in our observation,
ASD-IS children are characterized by rapid changes in be-
havioral symptoms following immune insults, as observed
in PANS children [13].
To test our hypothesis, we examined cytokine produc-
tion by purified PB Mo from ASD-IS and control ASD
and non-ASD subjects. We have reported previously re-
ported a high prevalence of NFA in young ASD children
with chronic GI symptoms, including ASD-IS children
[7]. Since the presence of NFA may indicate innate im-
mune abnormalities that predispose to NFA at least in
the gut mucosa [14], ASD and non-ASD controls were
further separated into two subgroups, children with or
without NFA. In addition, non-ASD/PANS subjects were
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children we recruited are often diagnosed with PANS by
CAM practitioners prior to entrance into this study.
Materials and methods
The study follows the protocols approved by the Institu-
tional Review Board at Rutgers-New Jersey Medical School.
Informed consent was obtained prior to blood sample
obtainment.
Study subjects
ASD subjects were recruited in the Pediatric Allergy/Im-
munology clinic. Diagnosis of ASD in the study subjects
was made at various autism diagnostic centers, including
ours. The ASD diagnosis was based on the Autism Diag-
nostic Observation Scale (ADOS) and/or the Autism
Diagnostic Inventory-Revisited (ADI-R), and these diagno-
ses were verified by the medical records. For those whose
ADOS and ADI-R records were not verified, the ADOS
and/or ADI-R was administered to confirm the diagnosis.
Any subjects with impaired hearing/eyesight, any motor
disability, such as cerebral palsy, or medical conditions
with known gene mutations were excluded from the
study. ASD subjects were also evaluated for their behav-
ioral symptoms, sleep habits, and adaptive skills by
using the Aberrant Behavior Checklist (ABC) [15], the
Children’s Sleep Habits Questionnaires (CSHQ)[16],
and the Vineland Adaptive Behavior Scale (VABS) [17],
respectively. For ASD subjects with limited expressive
language, the presence of physical pain was assessed by
using the Non-communicating Children’s Pain Checklist
(NCCPC) [18].
ASD subjects were further subdivided into three groups
(ASD-IS, ASD/NFA, and ASD/non-NFA) and each group
was defined as follows;
 ASD-IS children: ASD-IS children are defined as those
with a history of fluctuating behavioral symptoms
following immune insults (mainly microbial infection).
Symptoms must have been documented by individuals
other than parents, such as teachers/therapists, a
minimum of three times. In addition, a history of
persistent GI symptoms, often diagnosed as non-IgE
mediated food allergy (NFA - see next section for
diagnostic criteria), is required. Among the ASD-IS
subjects, 14/24 subjects were diagnosed with food
protein induced enterocolitis syndrome (FPIES), a
severe form of NFA, prior to enrollment in this
study, and two ASD-IS subjects were diagnosed
with eosinophilic esophagitis (EoE) on the basis of
biopsy results. These ASD-IS subjects reported to
have had loss of once-acquired cognitive skills
based on the reports of teachers, therapists and/or
previous records of developmental assessment.We defined ‘flares’ as worsening behavioral
symptoms following immune insults, despite the
resolution of acute conditions such as viral
syndrome (that is, the resolution of other
infectious symptoms if associated with a microbial
infection, lack of fever, and no other acute physical
symptoms associated with immune insults). Most
of the immune insults in this study were clinically
judged to be microbial infection (mainly viral
syndrome). In ASD-IS children, we obtained
samples at least once in the ‘flare’ and ‘non-flare’
states. Changes in behavioral symptoms by
parental reports were confirmed by reports from
teachers and other caregivers.
ASD/NFA controls: ASD children with a history of
NFA were defined as ASD children with a clinical
history of NFA that met the current diagnostic
criteria of NFA as detailed in the section of
non-ASD/NFA subjects. These subjects lacked the
fluctuating behavioral symptoms observed in the
ASD-IS children, following immune insults
(mainly microbial infection).
 ASD/non-NFA controls: ASD subjects without a
history of NFA or fluctuating behavioral symptoms
following immune insults.
Non-ASD controls included 3 groups as indicated in
the abstracts (Non-ASD/NFA subject, PANS subjects,
and normal controls without NFA or PANS) and each
group was defined as follows;
 Non-ASD/NFA subjects: Non-ASD subjects with
a history of NFA were recruited in the pediatric
A/I Clinic. NFA was diagnosed previously with the
resolution of GI symptoms following implementation
of a restricted diet (that is, avoidance of offending
food) and recurrence of symptoms with the
re-introduction of the offending food, following the
Food Allergy Diagnostic Guidelines, as there is no
specific histological finding in biopsy for NFA [19].
NFA patients are per definition, non-reactive to skin
prick testing and negative for food allergen-specific
serum IgE [19]. These non-ASD/NFA subjects did
not have significant GI symptoms that would affect
our assays at the time of sample obtainment. Most
of the non-ASD/NFA subjects were diagnosed
with food protein-induced enterocolitis syndrome
(FPIES), a severe form of NFA, based on the
clinical diagnostic criteria for NFA. Severe clinical
symptoms of FPIES often manifested as failure to
thrive in these subjects. FPIES, like other NFA, is
known to have no specific histological findings [19].
One non-ASD/NFA subject was diagnosed with
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IgE in the serum.
 PANS subjects: Children with PANS were diagnosed
clinically on the basis of the current diagnostic
criteria proposed by Swedo et al. [13]. PANS
subjects were typically developing without previous
history of developmental disability, learning
disability, or any other neuropsychiatric conditions
prior to onset of PANS symptoms.
 Normal controls: Typically developing, normal
control children without ASD, PANS, or NFA were
recruited in the pediatrics subspecialty clinic where
our A/I clinic also operated. Attempts were made to
match controls with ASD study subjects in terms of
gender, age, and ethnicity.Diagnosis of asthma and allergic rhinitis
Allergic rhinitis (AR) and allergic conjunctivitis (AC) were
diagnosed with positive skin prick test reactivity and/or
presence of allergen-specific IgE in the serum accompan-
ied by clinical features consistent with AR and AC [21,22].
Asthma diagnosis was based on the guidelines from the
Expert Panel Report 3 [23]. Asthma without skin test re-
activity to allergens and/or allergen-specific IgE antibodies
was categorized as non-atopic asthma [22].Antibody deficiency syndrome
Specific polysaccharide antibody deficiency (SPAD) was
diagnosed with detectable antibody (Ab) titers (more than
1.3 μg/ml) to fewer than 3 of 14 serotypes of Streptococcus
pneumonia in response to Pneumovax™ [24], a standard
diagnostic measure for SPAD.
Demographic information of the study subjects is sum-
marized in Table 1 and comorbid conditions are summa-




D-IS (N = 24) 11.8 (6.0-27.0) 19:5
D/NFA (N = 20) 7.5 (3.3-22) 15:5
D/non-NFA (N = 20) 12.9 (3.6-20.5) 17:3
on-ASD subjects
n-ASD/NFA (N = 16) 4.3 (1.2-20.6) 9:7
rmal control (N = 16) 10.5 (4.0-18.7) 10:6
NS (N = 18) 8.2 (5.0-15.8) 18:2
ge when the subject enrolled in the study.
bbreviations used: AA, African-American; ASD, autism spectrum disorder; ASD-IS,
ergy; PDD, pervasive developmental disorder, PANS, pediatric acute-onset neurop
addition to one PDD subject, two ASD/non-NFA subjects were diagnosed with ASample obtainment
PB samples were obtained by venipuncture after informed
consent was obtained. Efforts were made to obtain the PB
samples at the time of routine blood work in order to
minimize the number of venipunctures. For most of the
non-ASD/NFA, normal control, ASD/non-NFA, and ASD/
NFA groups, only one blood sample was taken. For PANS
and ASD-IS subjects, more than one blood sample was
obtained in an effort to have blood samples taken during
times when subject was in stable condition (‘non-flare’
samples) and when flare-ups of behavioral symptoms
following immune insults (‘flare’ samples) occurred.
Venipuncture was conducted by the physician, and if re-
quested, the site of venipuncture was numbed by the
application of topical lidocaine (Emla cream™).
Cell cultures
PBMCs were isolated by Ficoll-Hypaque density gradient
centrifugation. PB Mo were purified by negatively select-
ing PB Mo depleting T, B, natural killer, and DCs, using
magnetic beads labeled with anti-CD3, CD7, CD16, CD19,
CD56, CD123, and glycophorin A (Monocyte Isolation Kit
II, human; MILTENYI BIOTEC, Cambridge, MA, USA).
Innate immune responses were assessed by incubating
purified PB Mo (2.5×105 cells/ml) overnight with toll-like
receptor (TLR) 4 agonist (LPS; 0.1 μg/ml, GIBCO-BRL,
Gaithersburg, MD, USA), TLR2/6 agonist (zymosan;
50 μg/ml, Sigma-Aldrich, St. Louis, MO, USA), TLR7/8
agonist (CL097, water-soluble derivative of imidazoquino-
line, 20 μM, InvivoGen, San Diego, CA, USA), and dectin
1 agonist (heat killed Candida albicans as a source of
ß-lactam (109 cells/ml) - 10 μl/ml, InvivoGen) in RPMI
1640 with additives as previously described [25]. Over-
night incubation was adequate to induce the optimal re-
sponses in this setting.
Levels of proinflammatory (tumor necrosis factor-α
(TNF-α), interleukin-1ß (IL-1β), IL-6, IL-12p40, and IL-23)Ethnicity ASDb Diagnosis
Autism ASD PDD
1 Asian, 1 mixed, 22 W 17 6 1
2 Asians, 2 mixed, 16 W 11 4 5
1 AA, 3 mixed, 16 W 12 5 1c
16 W
2 mixed, 14 W
18 W
ASD-inflammatory subtype; F, female; M, male; NFA, non-IgE mediated food
sychiatric disorder; W, Caucasian.
sperger syndrome.
Table 2 Comorbid conditions of the study subjects
Seizure disorder Autoimmune conditions Allergic rhinitis Asthma Ab deficiency
ASDc subjects Atopic Non-atopic
ASD-IS (N = 24) 4/24 2/24a 2/24 0 3/24 3/24b
ASD/NFA (N = 20) 2/20 0 3/20 1/20 0 0
ASD/non-NFA (N = 20) 1/20 0 0 0 0 0
Non-ASD subjects
Non-ASD/NFA (N = 16) 0 0 0 0 0 0
Normal control (N = 16) 0 0 3/16 1/16 1/16 0
PANS (N = 18) 0 0 3/18 0 0 2/18
aOne subject was diagnosed with psoriasis and another subject was diagnosed with anti-phospholipid syndrome.
bAll subjects diagnosed with antibody deficiency syndrome were on IVIG treatment at the time of sample obtainment. All the subjects were shown to have
severely impaired responses to Pneumovax™.
cAbbreviations used; Ab, antibody; ASD, autism spectrum disorder; ASD-IS, ASD-inflammatory subtype; NFA, non-IgE mediated food allergy; PANS, pediatric acute
onset neuropsychiatric syndrome.
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ß (TGF-ß) and soluble TNF receptor II (sTNFRII)) cyto-
kines in the culture supernatant were then measured by
enzyme-linked immunosorbent assay (ELISA). For
ELISA, OptEIA™ Reagent Sets (BD Biosciences) were
used for IFN-γ, IL-1ß, IL-5, IL-6, IL-10, IL-12p40, and
TNF-α, and ELISA reagent set (R & D, Minneapolis,
MN, USA) were used for sTNFRII, IL-17 (IL-17A), and
TGF-ß. IL-23 ELISA kit was purchased from eBios-
ciences (San Diego, CA, USA). Intra- and intervariation
of cytokine levels were less than 5%.
Statistics
For comparison of test values with control values, a
Wilcoxon rank sum test was used. Differences in fre-
quency were tested with a Chi square (χ2) test and the
correlation was tested using linear regression analysis.
These tests were performed using R.3.1 (R-Develop-
ment Core Team 2011). A p value of <0.05 was consid-
ered to be statistically significant.
Results
Clinical findings
The prevalence of comorbid conditions is summarized in
Table 2. Seizure disorders requiring daily anti-seizureTable 3 Summary of the Aberrant Behavior Checklist (ABC), t
Children’s Sleep Habit Questionnaire (CSHQ) results
ASDd study group ABC subscale scorea
I (irritability) II (lethargy)
ASD-IS 13.7 ± 8.2b 8.9 ± 5.5
ASD/NFA 15.1 ± 8.3 12.2 ± 9.8
ASD/non-NFA 13.8 ± 9.6 10.1 ± 8.4
aABC subscales I, II, III in the ASD study groups were shown since ASD-IS children re
section and Figure. There are no significant differences in subscales III and V among
bResults of the ABC subscale and CSHQ total scores are expressed as average value
cResults of the VABS was expressed as a number of subjects whose adaptive scale a
dAbbreviations used; ASD, autism spectrum disorder; ASD-IS; ASD-inflammatory subtmedications were reported in 4/24 ASD-IS, 2/20 ASD/
NFA, and 1/20 ASD/non-NFA subjects, respectively
(Table 2). None of the non-ASD subjects were diagnosed
with seizure disorders. Autoimmune diseases were re-
ported in only two ASD-IS female subjects (anti-
phospholipid syndrome and psoriasis, respectively). Al-
lergic rhinitis was reported in 2/24 ASD-IS, 3/20 ASD/
NFA, 3/16 normal controls, and 3/17 PAN S subjects.
Thus the prevalence of well-described autoimmune dis-
eases or IgE mediated atopic disorders was not high in
any of the study groups. In addition, the frequency of
non-atopic asthma was not high in any of the study
groups as well (Table 2). Antibody deficiency syndrome,
as defined in the methods section, was diagnosed in 3/
24 ASD-IS subjects and 2/18 PANS subjects.
A developmental evaluation using either the Woodcock-
Johnson III test (WJIII) or school-reported IQ evaluation
in the year prior to the enrollment revealed that the gen-
eral intellectual ability (GIA) of most ASD subjects is <1st
percentile rank. However, the GIA of a few ASD subjects
ranked within the normal range (>5th percentile rank).
One Asperger subject in the ASD/non-NFA group had a
GIA ranked as the 98th percentile, although his adaptive
skills were in the 6th percentile based on the VABS. There
were no difference in scores of CSHQ, standardizedhe Vineland Adaptive Behavioral Scale (VABS), and the
VABS PR <1c CSHQ
IV (hyperactivity) Number (%) Total score
17.6 ± 8.2 18/24 (75%) 51.4 ± 5.0
21.1 ± 11.8 13/20 (65%) 49.7 ± 6.4
16.7 ± 10.1 16/20 (80%) 50.6 ± 7.2
vealed changes in these scales during ‘flare’ states as detailed in the results
the ASD groups.
± standard deviation (SD).
re <1st percentile rank (PR).
ype; NFA, non-IgE mediated food allergy.
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havioral scores by ABC among the ASD subjects
(Table 3). However, when ABC scores from the ASD-IS
subjects were compared during the ‘flare’ versus ‘non-
flare’ states as defined in the method section, ASD-IS sub-
jects experiencing ‘flares’ revealed significantly higher
scores in the ABC subdomains I (irritability) (P <0.005),
II (lethargy) (P <0.01), and IV (hyperactivity) (P <0.005)
(Figure 1).Cytokine production by peripheral blood mononuclear
cells versus peripheral blood monocytes
Initially, we tested whether purified PB Mo revealed cyto-
kine production profiles similar to those we had seen be-
fore with the use of PBMCs. The concentration of PB Mo
cells (0.25 × 106 cells/ml) was adjusted to be approximately
equivalent to the concentrations of PB Mo in PBMC cell
cultures (106 PBMCs/ml). PB Mo spontaneously produced
significantly higher amounts of most cytokines measured,
except for TGF-ß, than PBMCs (Figure 2).Cytokine production by peripheral blood monocytes
without stimuli or in responses to stimuli
Since significant changes in ABC subscale scores between
the ‘flare’ and ‘non-flare’ states were observed in ASD-IS
subjects (Figure 1), we examined if changes in cytokine






































Figure 1 In autism spectrum disorder-inflammatory subtype (ASD-IS)
the Aberrant Behavior Checklist (ABC) subdomains I (irritability), II (le
and ‘non-flare’ states (P <0.005 for subdomains I and IV and P <0.01Cytokine production in the absence of stimuli
Spontaneous production of IL-1ß and IL-6 by ‘flare’ ASD-
IS cells was higher than ‘non-flare’ASD-IS cells in matched
pair analysis (Tables 4 and 5 and Figure 3). These levels
were also higher than in most of the control cells (Tables 4
and 5). It should be noted that PANS cells revealed higher
spontaneous production of IL-1β, but there were no differ-
ence in the spontaneous production of IL-1β or IL-10 be-
tween ‘flare’ versus ‘non-flare’ states (P >0.05). The same
definition described for ASD-IS subjects, was used when
assessing ‘flare’ versus ‘non-flare’ states in PANS subjects.
In all the PANS subjects, ‘flare’ states were induced by mi-
crobial infection (mainly viral syndrome).
Cytokine production in response to stimuli
Because of the high levels of spontaneous cytokine pro-
duction by PB Mo, levels of most of the cytokines pro-
duced by PB Mo in response to stimuli were evaluated
after subtracting the values of the cytokines produced
spontaneously. The notable differences between the ‘flare’
versus ‘non-flare’ states of ASD-IS subjects were seen in
the production of IL-1ß and IL-6, as summarized in
Tables 4 and 5. Namely, IL-1ß production in response to
LPS and zymosan was higher in the ‘flare’ ASD-IS cells
than non-flare cells by matched-pair analysis (Figure 4)
and also higher than cells from most control groups ex-
cept for PANS cells. Although PANS cells tended to pro-
duce larger amounts of IL-1ß with stimuli, there were no
significant differences in IL-1ß production in the ‘flare’
























children, significant differences were observed in the scores of
thargy), III (stereotypy), and IV (hyperactivity) between the ‘flare’









































Figure 2 Comparison of production of cytokines (TNF-α, IL-1β, IL-10, IL-12p40, sTNRII, and TGF-β) (Panel A) and IL-6 (Panel B) by
purified peripheral blood monocytes (PB Mo) (0.25 × 106 cells/ml) and peripheral blood mononuclear cells (PBMCs) (106 cells/ml) from
the same blood samples of randomly selected subjects from all the study groups (N = 21). Each data point was shown as a mean cytokine
level ± SD. The concentration of PB Mo and PBMC monocytes in culture were set to be approximately the same. *; P <0.001, **; P <0.005
(Wilcoxon rank sum test).
Jyonouchi et al. Journal of Neuroinflammation 2014, 11:187 Page 7 of 13
http://www.jneuroinflammation.com/content/11/1/187among the study groups tested, the lowest production of
IL-1ß was observed in the ASD/NFA subjects (Table 4). In
contrast, IL-6 production in response to stimuli was lower
in response to zymosan in ‘flare’ ASD-IS cells than in
‘non-flare’ ASD-IS cells (Figure 4 and Table 5), and this
was also lower than that in normal control cells.
For the analysis of the IL-10 data, subtracting the spon-
taneous production of IL-10 could not be done. This is
because IL-10 production with stimuli, especially with
CL097 (TLR7/8 agonist), was lower than spontaneous IL-
10 production in substantial numbers of study subjects.
Thus, the results of IL-10 production were analyzed using
the ratio of IL-10 produced with stimuli and IL-10 pro-
duced in the absence of stimuli. When the results were
analyzed in this way, we found lower ratios of IL-10 in the
‘flare’ state of ASD-IS cells in response to LPS, zymosan,Table 4 IL-1β production by purified peripheral blood monoc
Study group Without stimuli [pg/ml] LPS
ASD-ISd
- Flare 736.6 ± 242.4a 2141
- Non-flare 424.8 ± 328.2 1596
ASD/NFA 404.2 ± 242.4 582.
ASD/non-NFA 471.9 ± 299.1 1592
Non-ASD/NFA 639.0 ± 424.0 1557
Normal control 361.2 ± 316.8 1580
PANS
- Flare 797.0 ± 598.8a 2310
- Non-Flare 731.9 ± 427.0a 1980
aSpontaneous production of IL-1β is higher in ‘flare’ ASD-IS cells than in ‘non-flare’ A
spontaneously is also higher than those produced by normal, ASD/NFA, and ASD/n
bIL-1ß levels produced by ‘flare’ ASD-IS cells in response to LPS and zymosan are hi
Figure 4. These levels are also higher than those produced by other control cells ex
cIL-1ß production by ASD/NFA cells in response to LPS, zymosan, and CL097 are low
dAbbreviations used; ASD, autism spectrum disorders, ASD-IS; ASD-inflammatory sub
allergy; PANS, pediatric acute-onset neuropsychiatric syndrome.and CL097 than most control groups (Table 6). Matched-
pair analysis also revealed significantly lower IL-1 ratio in
the ‘flare’ ASD-IS cells than by ‘’non-flare’ ASD-IS cells
(Figure 5). That is, ASD-IS ‘flare’ cells revealed signifi-
cantly lower production of IL-10 as compared to all the
control groups.
Discussion
This study addressed cytokine production profiles by PB
Mo in subgroups of ASD subjects categorized on the basis
of clinical features and allergy/immunology s as detailed
in the method section. To our knowledge, previous studies
addressing PB Mo functions in ASD children did not sub-
divide ASD subjects and involved smaller numbers of
ASD subjects than this study [26]. Also novel to this study,
three non-ASD controls groups were included, that is,ytes in the study groups
Zymosan CL097
.2 ± 819.4b 2665.0 ± 569.5b 3062.0 ± 888.2
± 57.5 1990.4 ± 664.7 2925.8 ± 862.0
7 ± 427.7c 373.7 ± 1620.7c 1056.8 ± 572.6c
.8 ± 599.4 566.3 ± 1823.2 2729.2 ± 1025.4
.5 ± 566.6 1826 ± 678.2 2373.6 ± 1220.0
.4 ± 428.5 1709.9 ± 597.2 2668.7 ± 609.1
.9 ± 1057.3 2124.2 ± 590.4 3065.1 ± 683.8
.8 ± 845.6 1888.1 ± 630.2 2615.6 ± 791.6
SD-IS cells in matched pair analysis as shown in Figure 3. IL-β levels produced
on-NFA (P <0.02 for ‘flare’ ASD-IS cells and P <0.05 for PANS cells).
gher than those by non-flare ASD-IS cells by matched pair analysis as shown in
cept for PANS cells.
est among the study groups (P <0.001).
type, IL, interleukin; LPS, lipopolysaccharide; NFA, non-IgE mediated food
Table 5 IL-6 production by purified peripheral blood monocytes in the study groups
Study group Without stimuli [pg/ml] LPS Zymosan
ASD-IS
- Flare 4541.7 ± 1332.8a 20662 ± 6181 936.6 ± 575.1b
- Non-Flare 3136.6 ± 1276.7 19420 ± 7051 1235.4 ± 1217
ASD/NFA 3682.7 ± 1613.3 17708 ± 10952 1352.4 ± 831.6
ASD/non-NFA 3827.3 ± 1467.4 18632 ± 10615 1281.7 ± 1068.5
Non-ASD/NFA 4029.8 ± 1246.1 20040 ± 6837 1334.0 ± 1031.4
Normal control 3102.8 ± 1225.4 17919 ± 10845 1716.1 ± 942.7
PANS
- Flare 4005.0 ± 1512.2 22455 ± 9097 1123.9 ± 1487.5
- Non-Flare 3726.9 ± 1143.0 19663 ± 9718 871.6 ± 1013.0
aSpontaneous IL-6 production by ‘flare’ ASD-IS cells was higher than ‘non-flare’ cells in matched pair analysis, as shown in Figure 4 and also higher than those
produced by ASD/NFA and normal control cells.
bIL-6 production by ‘flare’ ASD-IS cells in response to zymosan was lower than those produced by normal control cells (P <0.02) and also lower than the ‘non-flare’
ASD-IS cells in matched pair analysis (P <0.01).
cAbbreviations used; ASD, autism spectrum disorder; ASD-IS, ASD-inflammatory subtype; IL, interleukin; LPS, lipopolysaccharide; NFA, non-IgE mediated food



























B. IL 6A. IL 1ß
Figure 3 Production of IL-1ß (Panel A) and IL-6 (panel B) by autism spectrum disorder-inflammatory subtype (ASD-IS) cells in ‘flare’
and non-flare’ states. Levels of IL-1ß and IL-6 produced spontaneously by peripheral blood monocytes (PB Mo) were higher when in ‘flare’ than
during ‘non-flare’ states in ASD-IS children (P < 0.01for IL-1ß and P <0.005 for IL-6).


















































Figure 4 IL-1ß produced in response to lipopolysaccharide (LPS) (Panel A) and zymosan (Panel B) and IL-6 in response to zymosan
(Panel C) by ‘flare’ and ‘non-flare’ autism spectrum disorder-inflammatory subtype (ASD-IS) cells. The values were expressed as IL-1ß or
IL-10 produced with stimuli minus the values of IL-1ß or IL-10 produced spontaneously. IL-1ß production was higher by ‘flare’ ASD-IS cells than
in ASD-IS ‘non-flare’ cells (P <0.005 and P <0.01, respectively). IL-6 production was lower in ‘flare’ ASD-IS cells than ‘non-flare’ cells (P <0.01) by
Wilcoxin rank sum test.
Table 6 IL-10 production by purified peripheral blood monocytes in the study groups
The study group Without stimuli [pg/ml] LPS ratioa Zymosan CL097
ASD-ISc
- Flare 848.6 ± 344.8 1.48 ± 0.88b 1.15 ± 0.43b 0.55 ± 0.632
- Non-Flare 648.7 ± 382.1 2.64 ± 1.37 2.15 ± 1.09 1.23 ± 1.12
ASD/NFA 812.4 ± 365.5 1.96 ± 0.91 1.55 ± 0.75 0.89 ± 0.72
ASD/non-NFA 855.4 ± 364.7 1.93 ± 1.12 1.63 ± 1.03 0.93 ± 0.91
Non-ASD/NFA 948.5 ± 362.7 1.93 ± 1.38 1.66 ± 1.67 0.67 ± 0.51
Normal control 677.7 ± 290.0 2.40 ± 1.10 1.93 ± 1.06 0.76 ± 0.69
PANS
- Flare 791.7 ± 449.4 1.87 ± 0.95 1.82 ± 1.27 1.38 ± 0.99
- Non-Flare 945.8 ± 455.4 1.93 ± 1.14 1.66 ± 0.84 1.58 ± 1.07
aIL-10 production in response to LPS, zymosan, and CL097 were expressed as a ratio of IL-10 produced in these stimulants/IL-10 produced in the absence of
stimuli. It should be noted that IL-10 production tends to be lower in the presence of CL097 in most of the study groups.
bIL-10 production by ‘flare’ ASD-IS cells were lower than ‘non-flare’ ASD-IS cells with matched pair analysis as detailed in Figure IL-10 production by ‘flare’ ASD-IS
cells in response to LPS and zymosan were also lower than ASD/NFA and normal control cells (P <0.01). IL-10 production by ‘flare’ ASD-IS cells in response to
CL097 cells were also lower than those produced by PANS cells (P <0.01).
cAbbreviations used; ASD, autism spectrum disorder; ASD-IS, ASD-inflammatory subtype; IL, interleukin; LPS, lipopolysaccharide; NFA, non-IgE mediated food
allergy; PANS, pediatric acute-onset neuropsychiatric syndrome.












































Figure 5 Production of IL-10 in response to lipopoloysaccharide (LPS) (Panel A), zymosan (Panel B), and CL097 (Panel C) by autism
spectrum disorder-inflammatory subtype (ASD-IS) peripheral blood (PB) monocytes. The data are expressed as ratios of IL-10 produced
with stimuli divided by IL-10 produced in the absence of stimuli. ASD-IS cells revealed lower values in the ‘flare’ state than in the ‘non-flare’ state
(P <0.005 for LPS, P <0.05 for zymosan and CL097 by Wilcoxon rank sum test).
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controls without NFA or PANS. This experimental design
permits us to dissect what findings are specific for the
ASD-IS subjects. In addition, we analyzed the data de-
pending on the ‘flare’ versus ‘non-flare’ states in the ASD-
IS and PANS subjects. This is for testing our hypothesis
that changes in cytokine production profiles in PB Mo can
be associated with fluctuating behavioral symptoms fol-
lowing immune insults in the ASD-IS and PANS children.
In this study, parental impression of behavioral changes
in ASD-IS children following immune insults were verified
first, using the ABC and CSHQ. Behavioral symptoms, per
parental reports, would typically ‘flare’ for a prolonged
period following immune insults in ASD-IS children, des-
pite resolution of acute physical symptoms such as fever
or other signs of acute inflammation. When these results
were compared to baseline data obtained during ‘non-
flare’ states, we found significantly higher scores in subdo-
mains I (irritability), II (lethargy), and IV (hyperactivity) in
ABC scores (Table 3 and Figure 1) during ‘flares’ in ASD-
IS children. These findings support parental impression of
worsening behavioral symptoms in the ‘flare’ state follow-
ing immune insults. In the ASD-IS children, ABC scores
were assessed after resolution of acute symptoms of im-
mune insults such as upper respiratory infection. There-
fore, it is unlikely that behavioral changes are solely
attributed to the pain and/or discomfort associated with
acute illnesses.
Mounting evidence indicates that in other neuropsychi-
atric conditions such as schizophrenia, inflammatory cyto-
kines such as IL-1β and IL-6 have a role in onset andprogress of neuropsychiatric symptoms [27-31]. We have
reported previously that PBMCs obtained from ASD-IS
children produced reduced amounts of pro-inflammatory
cytokines (IL-1β and IL-6) and IL-10, a counter-regulatory
cytokine [1]. In these studies, most samples were obtained
when ASD-IS children were in the ‘non-flare’ states. Thus,
the altered PB Mo functions following a ‘flare’ may have
not been captured in our previous study. Alternatively,
other lineage cells, other than PB Mo, may have sup-
pressed the functions of PB Mo. In order to address these
functions of PB Mo more precisely, this study employed
purified PB Mo from ASD-IS children in the ‘flare’ versus
‘non-flare’ states.
First, we assessed the differences in cytokine produc-
tion profiles between PBMCs and PB Mo. We measured
cytokine production by PBMCs and PB Mo prepared
from the same blood samples in 21 subjects randomly
selected from all the study groups. As shown in Figure 2,
PB Mo spontaneously produced higher amounts of most
cytokines measured except for TGF-β. The concentra-
tion of PB Mo in the monocyte cultures was then ad-
justed to be roughly equivalent to that of the monocyte
concentration in PBMC cultures. Thus, it is very unlikely
that changes in cell concentrations are responsible for
the differences in spontaneous production of cytokines
by PBMCs and PB Mo. Instead, it is more likely that cyto-
kine production by PB Mo is suppressed by other lineage
cells present in PBMCs. For example, counter-regulatory
cytokines such as TGF-β and IL-10 produced by inducible
regulatory T (Treg) cells are known to suppress functions
of effecter cells including Mo [32]. The fact that
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kines in the periphery, was higher than that produced by
PB Mo indicates a possibility that TGF-β produced by
other lineage cells suppress spontaneous cytokine produc-
tion by PB Mo. Based on these findings, we reasoned that
the use of purified PB Mo will likely yield more informa-
tion regarding changes in monocyte function in ASD-IS
children.
Spontaneous production of cytokines by PB Mo was
then analyzed in all the study groups. The data from
ASD-IS and PANS children were analyzed in the ‘flare’
versus ‘non-flare’ states. PANS children are characterized
by acute onset neuropsychiatric changes following im-
mune insults (typically microbial infection) [18]. In our
experience, ASD-IS children are often diagnosed with
PANS on the basis of their fluctuating behavioral symp-
toms following immune insults. In the PANS children
recruited to this study, triggers of acute onset of neuro-
psychiatric symptoms varied from viral infection to bac-
terial infection, and none of them qualified for diagnosis
of PANDAS (pediatric autoimmune neuropsychiatric
diseases associated with streptococci) [13].
Our results of monocyte cytokine profiles revealed
higher spontaneous production of inflammatory cyto-
kines (IL-6, and IL-1β) in the ‘flare’ state than in the
‘non-flare’ states in ASD-IS children (Tables 4 and 5). In
PANS children, such changes were not observed. When
purified PB Mo were further stimulated by various stim-
uli of innate immunity, we found that despite increased
spontaneous production of IL-1β, ‘flare’ ASD-IS cells are
still capable of producing higher amounts of IL-1ß in re-
sponse to LPS and zymosan than ‘non-flare’ ASD-IS cells.
IL-1ß production by ‘flare’ ASD-IS cells are also higher
than other ASD/non-ASD control cells, except for PANS
cells. In contrast, IL-6 production by ‘flare’ASD-IS cells in
response to stimuli was equivalent or even lower than that
of ‘non-flare’ ASD-IS cells (Table 5 and Figure 4-C). It
should also be emphasized that such changes were not ob-
served in PANS children in ‘flare’ versus ‘non-flare’ states,
although they tended to exhibit increased production of
IL-1ß by PB Mo.
When in an inflammatory state or when subjects are re-
covering from inflammation, proinflammatory immune re-
sponses are generally suppressed by intrinsic suppressive
mechanisms of cells or by other lineages cells with suppres-
sive functions. This will help self-limit the inflammatory
processes. However, our results indicates that ASD-IS PB
Mo are still capable of producing significant amounts of IL-
1ß in response to stimuli even in the ‘flare state, despite
spontaneous production of high amounts of IL-1ß. Since
our assay used the purified PB Mo, our results indicate that
ASD-IS monocytes have impaired suppressive mechanisms
for IL-1ß production following activation. IL-6 production
did not increase in response to stimuli in ‘flare’ ASD-IScells. Production of functional IL-1ß requires additional en-
zymatic steps as opposed to other cytokines [33]. Therefore,
it is possible that ASD-IS children have impaired regulation
in the specific steps of IL-1ß production.
Dysregulated production of IL-1β and IL-6 has been
known to lead to chronic inflammatory conditions of the
CNS, joints, and GI tracts. For example, in cryopyrin asso-
ciated periodic fever syndrome (CAPS), autosomal domin-
ant mutation of cryopyrin leads to excessive production of
IL-1β, leading to chronic systemic inflammatory condition
affecting the CNS, joints, and other organs [34]. In juven-
ile idiopathic arthritis (JIA), excessive production of IL-6
and IL-1β (for systemic JIA) has been implicated in their
pathogenesis [35]. In these conditions, blockers of these
inflammatory cytokines have been effective for treating
these conditions [35,36]. Interestingly, in a rodent mater-
nal immune activation (MIA) model for autism, a single
injection of IL-6 to pregnant mice at gestational age of
12.5 days was reported to result in deficits in certain be-
haviors in the adult offspring [37]. Likewise, increased
serum levels of IL-1β in offspring have also been reported
in MIA models [38]. In patients with primary autoinflam-
matory conditions causing excessive action of IL-1ß, CNS
symptoms that partly resemble ASD behavioral symptoms
are well controlled by exogenous IL-1 blockers [34].
These reports along with our results indicate a possibil-
ity that changes in IL-1ß responses may be associated
with changes in behavioral symptoms observed in ASD-
IS children following immune insults. These findings
further support the need for mechanistic studies to as-
sess the feasibility for IL-1ß and/or IL-6 blockage strat-
egy as a strategy for treating ASD-IS children.
In chronic inflammation, IL-10, a counterregulatory
cytokine, is generally upregulated as part of the immuno-
regulatory actions [39]. However, in the ASD-IS children,
spontaneous IL-10 production did not differ between the
‘flare’ and ‘non-flare’ states. In addition, we found a signifi-
cant decrease in IL-10 production by ‘flare’ ASD-IS cells in
response to stimuli of innate immunity as compared to
‘non-flare’ ASD-IS cells (Figure 5). This was not found in
PANS children. Production of IL-10, one of the key reg-
ulators of inflammatory responses, by PB Mo is an im-
portant intrinsic regulatory mechanism for controlling
excessive inflammation [39]. In the state of microbial
infection, IL-10 production is often downregulated to
mount an immune defense effectively. However, exces-
sive, prolonged downregulation of IL-10 could cause
dysregulated, prolonged inflammation. Thus, our results
indicate a possibility that monocytes from ASD-IS chil-
dren also have intrinsic defects in regulatory mecha-
nisms of IL-10 production.
Lastly, it should be noted that the cytokine produc-
tion profiles in PB Mo differed between ASD-IS and
PANS subjects in this study. This finding indicates that
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what overlapping in ASD-IS and PANS subjects, under-
lying mechanisms may not be identical in these two
groups.
Conclusions
In summary, studies of purified PB Mo from ASD-IS
children indicate that they have dysregulated innate im-
mune responses. Specifically, these relate to the produc-
tion of IL-1ß and IL-10, revealing significant changes in
‘flare’ versus ‘non-flare’ states. These responses, for the
most part, were not observed in ASD/non-ASD controls.
These results indicate that further analysis of the regula-
tory mechanisms of PB Mo in ASD-IS subjects may lead
to the identification of biomarkers and even treatment
options for ASD-IS subjects who typically do not re-
spond well to the first-line therapeutic measures.
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